LEADER 01439nam a2200361 i 4500 001 991000806859707536 005 20020507173830.0 008 951025s1977 us ||| | eng 020 $a0821815989 035 $ab1075989x-39ule_inst 035 $aLE01302619$9ExL 040 $aDip.to Matematica$beng 041 0 $aengrus 082 0 $a519.2 084 $aAMS 60B12 100 1 $aOstrovskii, I. V.$0535105 245 10$aDecomposition of random variables and vectors /$cby Ju. V. Linnik and I. V. Ostrovskii ; [translated from the Russian by Israel Program for Scientific Translations ; translation edited by Judah Rosenblatt] 260 $aProvidence :$bAmerican Mathematical Society,$c1977 300 $aix, 380 p. ;$c24 cm. 490 0 $aTranslations of mathematical monographs,$x0065-9282 ;$v48 500 $aBibliography: p. 369-377. 500 $aIncludes indexes. 500 $aTit. orig.: Razlozheniia sluchainykh velichin i vektorov 650 4$aDecomposition 650 4$aDistribution theory 650 4$aRandom variables 700 1 $aLinnik, Iurii Vladimirovich 907 $a.b1075989x$b23-02-17$c28-06-02 912 $a991000806859707536 945 $aLE013 60B LIN21 (1977)$g1$i2013000038490$lle013$o-$pE0.00$q-$rl$s- $t0$u0$v0$w0$x0$y.i10855014$z28-06-02 996 $aDecomposition of random variables and vectors$9923145 997 $aUNISALENTO 998 $ale013$b01-01-95$cm$da $e-$feng$gus $h0$i1 LEADER 05155nam 22006374a 450 001 9910829843803321 005 20230617040243.0 010 $a1-280-85409-X 010 $a9786610854097 010 $a3-527-60753-6 010 $a3-527-60700-5 035 $a(CKB)1000000000377170 035 $a(EBL)482272 035 $a(OCoLC)70054438 035 $a(SSID)ssj0000140421 035 $a(PQKBManifestationID)11132252 035 $a(PQKBTitleCode)TC0000140421 035 $a(PQKBWorkID)10053445 035 $a(PQKB)11112891 035 $a(MiAaPQ)EBC482272 035 $a(EXLCZ)991000000000377170 100 $a20060628d2005 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aDNA pharmaceuticals$b[electronic resource] $eformulation and delivery in gene therapy, DNA vaccination and immunotherapy /$fedited by Martin Schleef 210 $aWeinheim $cWiley-VCH$dc2005 215 $a1 online resource (277 p.) 300 $aDescription based upon print version of record. 311 $a3-527-31187-4 320 $aIncludes bibliographical references and index. 327 $aDNA Pharmaceuticals; Preface; Contents; List of Contributors; Abbreviations; 1 DNA Vaccines - An Overview; 1.1 Rationale for DNA Vaccines; 1.2 Preclinical Proof of Concept; 1.3 Clinical Trials; 1.4 Second-Generation Vaccines; 1.5 Conclusions; References; 2 DNA as a Pharmaceutical - Regulatory Aspects; 2.1 Introduction; 2.2 Quality Requirements for DNA used as a Gene Therapy Product; 2.2.1 Introduction; 2.2.2 Production and Purification; 2.2.2.1 Raw Materials; 2.2.2.2 Antibiotics; 2.2.2.3 Solvents; 2.2.2.4 Fermentation; 2.2.2.5 Purification; 2.2.3 Cell Banking System Procedures 327 $a2.2.3.1 Generation and Characterization of Master and Working Cell Banks2.2.4 Product Characterization and Quality Criteria; 2.2.4.1 Identity; 2.2.4.2 Purity; 2.2.4.3 Adventitious Agents; 2.2.4.4 Potency; 2.3 Safety Studies for Clinical Trials; 2.3.1 General Considerations; 2.3.2 Conduct of Preclinical Safety Studies; 2.3.2.1 Regulations; 2.3.2.2 Design of an Appropriate Toxicology Program; 2.3.2.3 Single- and Repeat-Dose Toxicity Studies; 2.3.2.4 Safety of the Formulated Plasmid DNA; 2.3.2.5 Specific Safety Considerations; 2.3.2.6 Choice of Animal Model; 2.4 Special Issues 327 $a2.4.1 Comparability of Plasmid Gene Therapy Products2.4.2 Mixed Plasmid Preparations; 2.4.3 Plasmid Molecular Structure; 2.5 Biosafety Issues and Environmental Risk Assessment; References; 3 From Bulk to Delivery: Plasmid Manufacturing and Storage; 3.1 Introduction; 3.1.1 Gene Therapy; 3.1.2 DNA Vaccination; 3.2 Manufacturing of Plasmid DNA; 3.2.1 Bacterial Cultivation; 3.2.2 Plasmid DNA Purification; 3.2.3 Innovative Aspects in Plasmid Manufacturing; 3.3 Quality Control of Plasmid DNA Vectors; 3.3.1 Proteins, Ribonucleic Acid, and Lipopolysaccharides; 3.3.2 Chromosomal DNA 327 $a3.3.3 Plasmid Identity3.3.4 Plasmid Topology (Structural Homogeneity); 3.4 Plasmid Stability during Storage and Application; 3.4.1 Long-Term Stability of Plasmid DNA; 3.4.2 Lyophilization for Long-Term Storage; 3.4.3 Stability during Application; 3.5 Future Developments; References; 4 Minimized, CpG-Depleted, and Methylated DNA Vectors: Towards Perfection in Nonviral Gene Therapy; 4.1 Introduction; 4.2 The Mammalian Immune System as a Barrier to Nonviral Gene Delivery; 4.3 Strategies to Minimize DNA Vectors 327 $a4.3.1 Excision of a DNA Fragment Containing a Transgene Expression Cassette from Plasmid DNA4.3.2 Intramolecular Site-Specific Recombination Within a Bacterial Plasmid; 4.3.3 Synthesis of Minimized DNA Vectors by PCR; 4.3.4 Improvement of Minimized DNA Vector Yield and Purity; 4.4 Depletion of CpG Dinucleotides in the Bacterial Vector Backbone; 4.5 Methylation of CpG Dinucleotides in Plasmid DNA; 4.6 Towards an Ideal Nonviral Vector; 4.7 Conclusion; References; 5 Localized Nucleic Acid Delivery: A Discussion of Selected Methods; 5.1 Foreword; 5.2 Nucleic Acid Delivery - What For? 327 $a5.3 Nucleic Acid Delivery - How? 330 $aWith its focus on a completely novel class of pharmaceuticals, this book collates the hitherto scarce literature about DNA drug formulation keenly desired by biotechnologists, molecular biologists and pharmacists, as well as those working in the biotechnological and pharmaceutical industries.As such, this volume presents a wide range of gene delivery systems needed for different therapeutic applications. It fills the gap between research and clinical trials and describes pharmaceutical fundamentals for the development of efficient DNA pharmaceuticals. 606 $aDNA vaccines 606 $aGene therapy 606 $aImmunotherapy 615 0$aDNA vaccines. 615 0$aGene therapy. 615 0$aImmunotherapy. 676 $a615.372 676 $a616.0796 701 $aSchleef$b M$g(Martin)$01663535 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910829843803321 996 $aDNA pharmaceuticals$94022990 997 $aUNINA LEADER 02896nam 2200637 450 001 9910807370303321 005 20231206223850.0 010 $a1-4411-1048-8 010 $a1-283-12236-7 010 $a9786613122360 010 $a1-4411-1009-7 035 $a(CKB)2670000000093444 035 $a(EBL)711073 035 $a(OCoLC)727649578 035 $a(SSID)ssj0000521237 035 $a(PQKBManifestationID)12205181 035 $a(PQKBTitleCode)TC0000521237 035 $a(PQKBWorkID)10522841 035 $a(PQKB)10231599 035 $a(Au-PeEL)EBL5309591 035 $a(CaPaEBR)ebr11518559 035 $a(OCoLC)1027140004 035 $a(NBER)w21102 035 $a(MiAaPQ)EBC5309591 035 $a(MiAaPQ)EBC711073 035 $a(EXLCZ)992670000000093444 100 $a20180315h20112011 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aBorrowing from the future $ea faith-based approach to intergenerational equity /$fAnn Morisy 210 1$aLondon, [England] ;$aNew York, New York :$cContinuum,$d2011. 210 4$dİ2011 215 $a1 online resource (238 p.) 300 $aIncludes index. 311 $a1-4411-2536-1 320 $aIncludes bibliographical references and index. 327 $aCover; Contents; Acknowledgements; Introduction; 1 Uniquely favoured? Uniquely selfish? Uniquely fearful?; 2 What's the score?; 3 Borrowing from the future; 4 Second chance theology; 5 Age has its purpose?; 6 Retirement matters; 7 Inheritance matters; 8 An epidemic of narcissism?; 9 Pivot: Paying our proper dues; 10 Old people . . . don't make me laugh; 11 Resentment: The dastardly bushfire; Questions for Discussion; Index; A; B; C; D; E; F; G; H; I; J; K; L; M; N; O; P; Q; R; S; T; U; V; W; Z 330 $aThis is a new but pressing issue. The pukka term is 'intergenerational equity' and gerontologists and policy makers have seen it coming for some time. The recession has added to the intensity of the issue, as those in the later stage of life are less likely to be hard hit by changes in relation to pension provision, unemployment and the steep challenge of getting a foot on the property ladder. Societies throughout history have been used to investing in their children, today the worry is the ever rising cost of eldercare. There are profound, but unacknowledged repercussions of the age p 606 $aSocial policy 606 $aBaby boom generation 606 $aIntergenerational relations 615 0$aSocial policy. 615 0$aBaby boom generation. 615 0$aIntergenerational relations. 676 $a248.483 700 $aMorisy$b Ann$01705424 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910807370303321 996 $aBorrowing from the future$94096675 997 $aUNINA